How this immunotherapy combination is thought to work

There are many factors that contribute to cancer developing in the body. By targeting some of them, this unique combination is designed to fight advanced melanoma. It is thought to do so in two ways that distinguish it from other treatments.

  1. TECENTRIQ immunotherapy helps reactivate the immune system to recognize cancer cells in the body. Sometimes cancer cells can go undetected by your immune system. One way this happens is through a protein called programmed death-ligand 1, or PD-L1. TECENTRIQ is designed to block PD-L1 on cancer cells to prevent this from happening. By blocking PD-L1, TECENTRIQ is thought to reveal cancer cells. This helps your immune system recognize and target your cancer. TECENTRIQ may also affect normal cells.

  2. While TECENTRIQ is designed to block PD-L1, COTELLIC and ZELBORAF are designed to target the MAPK pathway, which includes two proteins that play a part in cell growth, MEK and BRAF. When you have a mutation in the BRAF gene (known as the BRAF V600 mutation), cells duplicate uncontrollably. By blocking this process, it may help slow down the speed at which cancer cells grow.

By targeting both of these processes—PD-L1 and the MAPK pathway—this combination therapy may help with the immune system response and also slow down the rapid growth of cancer cells, allowing the body to fight cancer.

How treatment may help

Learn more about the potential benefits and possible risks